Carflizomib is Extraordinarily Active in Myeloma Mainstay drug for physicians and patients

ASHReport has 317 videos Subscribe Here

Description: Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib is extraordinarily active in myeloma and mainstay drug for physicians and patients at the 2017 American Society of Hematology.
Shared By : ASHReport
Posted on : 01/23/18
Added : 1 year ago
Category : Multiple Myeloma